1. Home
  2. URGN vs TK Comparison

URGN vs TK Comparison

Compare URGN & TK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • TK
  • Stock Information
  • Founded
  • URGN 2004
  • TK 1973
  • Country
  • URGN United States
  • TK Bermuda
  • Employees
  • URGN N/A
  • TK N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • TK Marine Transportation
  • Sector
  • URGN Health Care
  • TK Consumer Discretionary
  • Exchange
  • URGN Nasdaq
  • TK Nasdaq
  • Market Cap
  • URGN 465.9M
  • TK 554.2M
  • IPO Year
  • URGN 2017
  • TK 1995
  • Fundamental
  • Price
  • URGN $9.67
  • TK $6.64
  • Analyst Decision
  • URGN Strong Buy
  • TK
  • Analyst Count
  • URGN 7
  • TK 0
  • Target Price
  • URGN $37.21
  • TK N/A
  • AVG Volume (30 Days)
  • URGN 499.1K
  • TK 805.8K
  • Earning Date
  • URGN 05-12-2025
  • TK 05-08-2025
  • Dividend Yield
  • URGN N/A
  • TK N/A
  • EPS Growth
  • URGN N/A
  • TK N/A
  • EPS
  • URGN N/A
  • TK 1.42
  • Revenue
  • URGN $90,398,000.00
  • TK $1,220,374,000.00
  • Revenue This Year
  • URGN $38.65
  • TK N/A
  • Revenue Next Year
  • URGN $118.69
  • TK N/A
  • P/E Ratio
  • URGN N/A
  • TK $4.67
  • Revenue Growth
  • URGN 9.29
  • TK N/A
  • 52 Week Low
  • URGN $8.94
  • TK $5.65
  • 52 Week High
  • URGN $20.70
  • TK $9.95
  • Technical
  • Relative Strength Index (RSI)
  • URGN 41.45
  • TK 53.82
  • Support Level
  • URGN $8.94
  • TK $6.23
  • Resistance Level
  • URGN $10.83
  • TK $6.60
  • Average True Range (ATR)
  • URGN 0.79
  • TK 0.31
  • MACD
  • URGN -0.07
  • TK 0.04
  • Stochastic Oscillator
  • URGN 29.67
  • TK 90.83

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About TK Teekay Corporation

Teekay Corp Ltd is engaged in providing international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services, and conventional tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.

Share on Social Networks: